← Back to screener

Olema Pharmaceuticals, Inc. OLMA

Rank #2066 · Nasdaq · $0.6B market cap
⚠ Going-concern flag — the auditor (Ernst & Young LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.
Score
34.9
P/E
-4.7
P/B
2.41
ROE
-51.0%
Op. Margin
–%
Debt Ratio
17%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Weak

P/E -4.7x, P/B 2.41x. Ranks in the top 66% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -51.0%. Ranks in the top 88% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 17%. Ranks in the top 12% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2021–$-0.0B$-0.0B$-0.0B–-55
2022–$-0.1B$-0.1B$0.3B–3
2023–$-0.1B$-0.1B$0.3B–6
2024–$-0.1B$-0.1B$0.2B–12
2025–$-0.1B$-0.1B$0.3B–17

← See the full screener